Harmony Biosciences President Awarded $4.33M Worth of Stock Options

Thursday, 1 June 2023, 17:02:10
Jeffrey Dayno , President at Harmony Biosciences (NASDAQ: HRMY ), reported a large acquisition of company stock options on May 31, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Dayno, President at Harmony Biosciences, a company in the Health Care sector, was just awarded stock options worth 125,000 shares of HRMY. The options give Dayno the right to buy the company”s stock at $35.56 per share. Harmony Biosciences shares are trading up 0.29% at $34.68 at the time of this writing on Thursday morning. Since the current price is $34.68, this makes Dayno”s 125,000 shares worth … Full story available on Benzinga.com
— Benzinga

Harmony Biosciences: A Company With Solid Fundamentals (Rating Upgrade)

Wednesday, 24 May 2023, 22:53:01
Harmony Biosciences sells Wakix for narcolepsy. HRMY is pursuing label expansions, but has been under short seller attack. Click to read our take.
— Seeking Alpha

State Board of Administration of Florida Retirement System Acquires New Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Monday, 22 May 2023, 10:58:45
State Board of Administration of Florida Retirement System bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 4,635 shares of the company’s stock, valued at approximately $255,000. A number of other large investors have also added to or reduced their […]
— The AM Reporter

HBM Healthcare Investments year-end results 2022/2023

Friday, 12 May 2023, 06:30:30
HBM Healthcare Investments AG / Key word(s): Personnel 12-May-2023 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. HBM Healthcare Investments reports a loss of CHF 146 million for the 2022/2023 financial year. Inflation and rising interest rates led to declining valuations for technology and growth stocks around the globe. Four profitable acquisitions, two IPOs, and the value increase of several operationally successful portfolio companies did not compensate for the decline. Net asset value per share (NAV) -7.4 percent, share price -18.9 percent Healthcare sector remains attrac tive and HBM Healthcare Investments a predestined investment instrument Continuation of distribution policy with a yield of 3.5 percent Declining valuations for growth stocks The market environment with inflation and rising interest rates had a negative impact on the valuations of technology and growth stocks. The biotechnology sector was no exception and the segment of small and medium-sized companies in particular – the main focus of HBM Healthcare”s investment strategy – underwent a significant valuation correction.
— EQS News

Harmony Biosciences Earnings Perspective: Return On Capital Employed

Monday, 8 May 2023, 16:47:29
According to Benzinga Pro, during Q1, Harmony Biosciences (NASDAQ: HRMY ) earned $29.48 million, a 39.22% increase from the preceding quarter. Harmony Biosciences”s sales decreased to $119.13 million, a 7.16% change since Q4. In Q4, Harmony Biosciences earned $48.51 million, and total sales reached $128.31 million. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company”s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
— Benzinga